AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33746024 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy (ticagrelor 90 mg twice daily and rivaroxaban 15 mg once daily)
Number of subjects: 106
Study 33746024 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy (aspirin 100 mg and clopidogrel 75 mg once daily combined with dose-adjusted warfarin)
Number of subjects: 106
Study 33746024 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy (ticagrelor plus rivaroxaban)
Number of subjects: 106
Study 33746024 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy (warfarin plus dual antiplatelet therapy)
Number of subjects: 106
Study 35290512 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver navigation intervention using eSNAP social resource visualization
Number of subjects: 15
Study 35290512 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver navigation intervention
Number of subjects: 15
Study 33245237 — intervention group
Group type: EXPERIMENTAL
Intervention: Stochastic Negative Addition (SNA)
Number of subjects: 0
Study 33245237 — intervention group
Group type: COMPARATOR
Intervention: y-randomized controls
Number of subjects: 0
Study 32935904 — intervention group
Group type: EXPERIMENTAL
Intervention: Nopal fiber 20 g/day
Number of subjects: 60
Study 32935904 — intervention group
Group type: EXPERIMENTAL
Intervention: Nopal fiber 30 g/day
Number of subjects: 60
Study 32935904 — intervention group
Group type: COMPARATOR
Intervention: Placebo (30 g/day dextrose)
Number of subjects: 60
Study 32380988 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% oxygen
Number of subjects: 68
Study 32380988 — intervention group
Group type: COMPARATOR
Intervention: 21% oxygen (air)
Number of subjects: 68
Study 35569806 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal shared decision-making intervention
Number of subjects: 228
Study 35569806 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 228
Study 33241739 — intervention group
Group type: EXPERIMENTAL
Intervention: Role-play with booster training
Number of subjects: 0
Study 33241739 — intervention group
Group type: COMPARATOR
Intervention: Role-play without booster training
Number of subjects: 0
Study 33241739 — intervention group
Group type: COMPARATOR
Intervention: No role-play with booster training
Number of subjects: 0
Study 33241739 — intervention group
Group type: COMPARATOR
Intervention: No role-play without booster training
Number of subjects: 0
Study 32682394 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Oral Hydration (EOH) - small amount of drinking water after recovery of swallowing reflex
Number of subjects: 2000
Study 32682394 — intervention group
Group type: COMPARATOR
Intervention: Delayed Oral Hydration (DOH) - water administered at 4 hours post-anesthesia
Number of subjects: 2000
Study 35617974 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotion
Number of subjects: 550
Study 35617974 — intervention group
Group type: EXPERIMENTAL
Intervention: Cream
Number of subjects: 550
Study 35617974 — intervention group
Group type: EXPERIMENTAL
Intervention: Gel
Number of subjects: 550
Study 35617974 — intervention group
Group type: EXPERIMENTAL
Intervention: Ointment
Number of subjects: 550
Study 33769510 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus aspiration
Number of subjects: 10732
Study 33769510 — intervention group
Group type: COMPARATOR
Intervention: PCI alone
Number of subjects: 10732
Study 32776570 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for ARFID (CBT-AR), 20–30 sessions delivered in family-based or individual format.
Number of subjects: 25
Study 32776570 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for ARFID (CBT-AR)
Number of subjects: 25
Study 35485618 — intervention group
Group type: EXPERIMENTAL
Intervention: ATVV stimulation therapy
Number of subjects: 107
Study 35485618 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 107
Study 32285047 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprietary Lactobacillus casei
Number of subjects: 0
Study 32285047 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33627250 — intervention group
Group type: COMPARATOR
Intervention: IMN alone (Group 1)
Number of subjects: 154
Study 33627250 — intervention group
Group type: EXPERIMENTAL
Intervention: IMN + 1 Poller screw (Group 2)
Number of subjects: 154
Study 33627250 — intervention group
Group type: EXPERIMENTAL
Intervention: IMN + 2 Poller screws (Group 3)
Number of subjects: 154
Study 33627250 — intervention group
Group type: COMPARATOR
Intervention: Control (IMN alone)
Number of subjects: 154
Study 33627250 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 154
Study 35388029 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly sessions of psychotherapy for 12 months
Number of subjects: 10
Study 35388029 — intervention group
Group type: COMPARATOR
Intervention: Standard of care treatment
Number of subjects: 10
Study 33496870 — intervention group
Group type: EXPERIMENTAL
Intervention: CTTQ
Number of subjects: 18
Study 33496870 — intervention group
Group type: COMPARATOR
Intervention: Parkedale
Number of subjects: 18
Study 32684741 — intervention group
Group type: EXPERIMENTAL
Intervention: Yikou-Sizi powder hot compress on Shenque acupuncture point combined with rapid rehabilitation technique
Number of subjects: 0
Study 32684741 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 0
Study 34304330 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based delivery (HBD)
Number of subjects: 2489
Study 34304330 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence clubs (AC)
Number of subjects: 2489
Study 34304330 — intervention group
Group type: COMPARATOR
Intervention: Facility-based delivery (SoC)
Number of subjects: 2489
Study 34304330 — intervention group
Group type: EXPERIMENTAL
Intervention: Community models of ART delivery
Number of subjects: 2489
Study 32991776 — intervention group
Group type: EXPERIMENTAL
Intervention: CIN risk score model based on LVEF < 40%, acute coronary syndrome (ACS), eGFR < 60, and contrast volume > 300 mL.
Number of subjects: 1113
Study 32991776 — intervention group
Group type: EXPERIMENTAL
Intervention: CIN risk score model
Number of subjects: 1113
Study 32991776 — intervention group
Group type: COMPARATOR
Intervention: Mehran score
Number of subjects: 1113
Study 34811787 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher threat messages
Number of subjects: 892
Study 34811787 — intervention group
Group type: COMPARATOR
Intervention: Lower threat messages
Number of subjects: 892
Study 34697566 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose Betaloc (≤47.5 mg)
Number of subjects: 60
Study 34697566 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-dose Betaloc (47.5-95 mg)
Number of subjects: 60
Study 34697566 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose Betaloc (142.5-190 mg)
Number of subjects: 60
Study 34697566 — intervention group
Group type: COMPARATOR
Intervention: Control group (No Betaloc)
Number of subjects: 60
Study 33963005 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated oxygen titration with the VDL1.1 algorithm
Number of subjects: 35
Study 33963005 — intervention group
Group type: COMPARATOR
Intervention: Manual control
Number of subjects: 35
Study 33597355 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence imaging with 5-aminolevulinic acid (5-ALA)
Number of subjects: 0
Study 33597355 — intervention group
Group type: COMPARATOR
Intervention: White light imaging
Number of subjects: 0
Study 32246680 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Level Laser Therapy (LLLT)
Number of subjects: 60
Study 32246680 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous Electric Nerve Stimulation (TENS)
Number of subjects: 60
Study 35152918 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 μg vitamin B12 daily for a year
Number of subjects: 600
Study 35152918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study 32674594 — intervention group
Group type: EXPERIMENTAL
Intervention: Various treatments for COVID-19 (specific interventions not detailed)
Number of subjects: 0
Study 32674594 — intervention group
Group type: COMPARATOR
Intervention: Fixed time-point methods (specific interventions not detailed)
Number of subjects: 0
Study 34793864 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative accelerated radiotherapy (AF) with 43 fractions, total dose of 68 Gy in 4.5 weeks followed by surgery
Number of subjects: 250
Study 34793864 — intervention group
Group type: COMPARATOR
Intervention: Postoperative conventionally fractionated radiotherapy (CF), total dose of 60 or 66 Gy in 6-7 weeks
Number of subjects: 250
Study 34793864 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative accelerated radiotherapy (AF)
Number of subjects: 250
Study 34793864 — intervention group
Group type: COMPARATOR
Intervention: Postoperative conventionally fractionated radiotherapy (CF)
Number of subjects: 250
Study 35192788 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT) in addition to standard medical care (SMC)
Number of subjects: 155
Study 35192788 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care (SMC)
Number of subjects: 155
Study 34444004 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate Treatment Group (IT, n = 10)
Number of subjects: 20
Study 34444004 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control Group (WL, n = 10)
Number of subjects: 20
Study 32957340 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous low-dose ketamine
Number of subjects: 0
Study 32957340 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study 36000293 — intervention group
Group type: EXPERIMENTAL
Intervention: Test linezolid tablet (600 mg)
Number of subjects: 48
Study 36000293 — intervention group
Group type: COMPARATOR
Intervention: Reference linezolid tablet (600 mg)
Number of subjects: 48
Study 36000293 — intervention group
Group type: EXPERIMENTAL
Intervention: Test and Reference linezolid tablets
Number of subjects: 48
Study 34617684 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive video
Number of subjects: 558
Study 34617684 — intervention group
Group type: COMPARATOR
Intervention: Combined videos (regular and interactive)
Number of subjects: 558
Study 32206772 — intervention group
Group type: EXPERIMENTAL
Intervention: obinutuzumab+venetoclax (VenG)
Number of subjects: 421
Study 32206772 — intervention group
Group type: COMPARATOR
Intervention: obinutuzumab+chlorambucil (GClb)
Number of subjects: 421
Study 35627343 — intervention group
Group type: EXPERIMENTAL
Intervention: GeMuKi lifestyle intervention (brief counseling on nutrition and physical activity during prenatal check-ups)
Number of subjects: 0
Study 34302417 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered transitional care model
Number of subjects: 986
Study 34302417 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 986
Study 33735404 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis name (AMD) in claims’ data
Number of subjects: 1400
Study 33735404 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis name (AMD) combined with fluorescence fundus angiography and/or anti‐VEGF treatment
Number of subjects: 1400
Study 33735404 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis name (AMD) combined with AMD treatment
Number of subjects: 1400
Study 32928844 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-week mindfulness-based intervention
Number of subjects: 60
Study 32928844 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 60
Study 35085443 — intervention group
Group type: EXPERIMENTAL
Intervention: Online administration of the Test of Narrative Language-Second Edition (TNL-2)
Number of subjects: 357
Study 35085443 — intervention group
Group type: COMPARATOR
Intervention: In-person administration of the Test of Narrative Language-Second Edition (TNL-2)
Number of subjects: 357
Study 32422285 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical castor oil applied to one eye, twice daily for 4 weeks
Number of subjects: 26
Study 32422285 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical castor oil applied to one eye
Number of subjects: 26
Study 32659755 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic AV fistula ligature
Number of subjects: 28
Study 32659755 — intervention group
Group type: COMPARATOR
Intervention: Control group (no immediate ligature)
Number of subjects: 28
Study 33629971 — intervention group
Group type: EXPERIMENTAL
Intervention: Weightlifting (WL) resistance training
Number of subjects: 45
Study 33629971 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric (P) training
Number of subjects: 45
Study 33629971 — intervention group
Group type: COMPARATOR
Intervention: Control (C) group
Number of subjects: 45
Study 34554379 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric Surgery (BSG)
Number of subjects: 0
Study 34554379 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 0
Study 32018166 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA
Number of subjects: 21
Study 32018166 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA
Number of subjects: 21
Study 35863559 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra 100 mg, three times per week via the hemodialysis circuit for 24 weeks
Number of subjects: 80
Study 35863559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 35863559 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 80
Study 34521687 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab 300 mg IV every 4 weeks for 24 weeks
Number of subjects: 66
Study 34521687 — intervention group
Group type: COMPARATOR
Intervention: Placebo every 4 weeks for 24 weeks
Number of subjects: 66
Study 34521687 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab 300 mg IV
Number of subjects: 66
Study 34521687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 33472677 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass drug administration (MDA) for soil-transmitted helminths (STH)
Number of subjects: 0
Study 33472677 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33472677 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention arm
Number of subjects: 0
Study 34999593 — intervention group
Group type: EXPERIMENTAL
Intervention: info + prompt
Number of subjects: 240
Study 34999593 — intervention group
Group type: EXPERIMENTAL
Intervention: info + plan
Number of subjects: 240
Study 34999593 — intervention group
Group type: EXPERIMENTAL
Intervention: info + prompt + plan
Number of subjects: 240
Study 34999593 — intervention group
Group type: COMPARATOR
Intervention: no prompt
Number of subjects: 240
Study 34999593 — intervention group
Group type: COMPARATOR
Intervention: no plan
Number of subjects: 240
Study 33388390 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful walking (MW) intervention plus a FitBit device
Number of subjects: 38
Study 33388390 — intervention group
Group type: COMPARATOR
Intervention: FitBit device only
Number of subjects: 38
Study 34812692 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammography screening
Number of subjects: 0
Study 34812692 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33845881 — intervention group
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine (300 mg/kg equivalent to 20 gr as a slow single intravenous injection on the first day of hospitalization)
Number of subjects: 40
Study 33845881 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Sterile water for injection, identical in appearance to N-Acetylcysteine)
Number of subjects: 40
Study 33106170 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccinated group (200 participants)
Number of subjects: 400
Study 33106170 — intervention group
Group type: COMPARATOR
Intervention: BCG unvaccinated control group (200 participants)
Number of subjects: 400
Study 34847228 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferiprone (n = 152)
Number of subjects: 228
Study 34847228 — intervention group
Group type: COMPARATOR
Intervention: Deferoxamine (n = 76)
Number of subjects: 228
Study 34847228 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferiprone
Number of subjects: 228
Study 32781987 — intervention group
Group type: EXPERIMENTAL
Intervention: PDSAFE intervention
Number of subjects: 474
Study 32781987 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 474
Study 36075260 — intervention group
Group type: EXPERIMENTAL
Intervention: Rezvilutamide plus ADT (240 mg daily)
Number of subjects: 654
Study 36075260 — intervention group
Group type: COMPARATOR
Intervention: Bicalutamide plus ADT (50 mg daily)
Number of subjects: 654
Study 33004724 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio Distraction
Number of subjects: 60
Study 33004724 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual Distraction (AVD) (VR)
Number of subjects: 60
Study 33004724 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile Phone Game Distraction
Number of subjects: 60
Study 33004724 — intervention group
Group type: COMPARATOR
Intervention: Tell‐Show‐Do (TSD)
Number of subjects: 60
Study 35689084 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Dose atDCS
Number of subjects: 42
Study 35689084 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Dose atDCS
Number of subjects: 42
Study 35689084 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 42
Study 35689084 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined atDCS group (Low-Dose + High-Dose)
Number of subjects: 42
Study 33932261 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term splinting (2-3 months)
Number of subjects: 512
Study 33932261 — intervention group
Group type: COMPARATOR
Intervention: Short-term splinting (1 month or less)
Number of subjects: 512
Study 33932261 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term splinting
Number of subjects: 512
Study 33932261 — intervention group
Group type: COMPARATOR
Intervention: Short-term splinting
Number of subjects: 512
Study 36001383 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab with standard platinum-based chemotherapy
Number of subjects: 413
Study 36001383 — intervention group
Group type: COMPARATOR
Intervention: Standard platinum-based chemotherapy
Number of subjects: 413
Study 32740081 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz translumbosacral neuromodulation therapy (TNT)
Number of subjects: 33
Study 32740081 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 Hz translumbosacral neuromodulation therapy (TNT)
Number of subjects: 33
Study 32740081 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 Hz translumbosacral neuromodulation therapy (TNT)
Number of subjects: 33
Study 32740081 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz and 5 Hz translumbosacral neuromodulation therapy (TNT)
Number of subjects: 33
Study 32118463 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily text messages containing accurate drinking norms (n = 61)
Number of subjects: 121
Study 32118463 — intervention group
Group type: COMPARATOR
Intervention: Historical facts (control group, n = 60)
Number of subjects: 121
Study 36394093 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-session tDCS
Number of subjects: 36
Study 36394093 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-session tDCS
Number of subjects: 36
Study 36394093 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 36
Study 34266574 — intervention group
Group type: EXPERIMENTAL
Intervention: Coexisting aortic dilations
Number of subjects: 14989
Study 34266574 — intervention group
Group type: EXPERIMENTAL
Intervention: Coexisting iliac dilations
Number of subjects: 14989
Study 34266574 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 14989
Study 34266574 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing body surface area
Number of subjects: 14989
Study 34266574 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 14989
Study 34266574 — intervention group
Group type: EXPERIMENTAL
Intervention: Familial disposition
Number of subjects: 14989
Study 34266574 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation
Number of subjects: 14989
Study 34266574 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 14989
Study 34266574 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute myocardial infarction
Number of subjects: 14989
Study 34266574 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 14989
Study 33285079 — intervention group
Group type: EXPERIMENTAL
Intervention: Transbronchial lung cryobiopsy (TBLC)
Number of subjects: 65
Study 32125382 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation and catheter ablation
Number of subjects: 0
Study 32125382 — intervention group
Group type: COMPARATOR
Intervention: Catheter ablation alone
Number of subjects: 0
Study 33609182 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral nerve block (FNB)
Number of subjects: 64
Study 33609182 — intervention group
Group type: COMPARATOR
Intervention: Adductor canal block (ACB)
Number of subjects: 64
Study 35972453 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone vaginal tablets, 100 mg twice daily, starting from the day of embryo transfer
Number of subjects: 488
Study 35972453 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 488
Study 34120186 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Number of subjects: 415
Study 32538014 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional moxibustion
Number of subjects: 216
Study 32538014 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion light
Number of subjects: 216
Study 32538014 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion heat
Number of subjects: 216
Study 33645069 — intervention group
Group type: EXPERIMENTAL
Intervention: Icaritin (5 μmol·L(‐1))
Number of subjects: 0
Study 33645069 — intervention group
Group type: EXPERIMENTAL
Intervention: Icaritin (10 μmol·L(‐1))
Number of subjects: 0
Study 33645069 — intervention group
Group type: EXPERIMENTAL
Intervention: Icaritin (20 μmol·L(‐1))
Number of subjects: 0
Study 33645069 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 616905942 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 30